Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 3 - What They Never Told You

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

MarketBeat

Arvinas Q1 Earnings Call Highlights

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

MarketBeat

White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years

The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Index Futures Climb as U.S.-Iran Ceasefire Holds, JOLTs Report and Earnings in Focus

June S&P 500 E-Mini futures (ESM26) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.47% this morning, supported by lower oil prices as the ceasefire in the Middle East appeared to be holding.

Barchart

Are Wall Street Analysts Bullish on Pfizer Stock?

Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Barchart

The COVID Reckoning Doesn't Go Far Enough

Real medical freedom will require something greater than replacing the public health establishment: ending the FDA's monopoly.

Reason

Read news from The Economist, FT, and more,
with one subscription

Will RFK Jr’s podcast actually address Americans’ public health concerns?

Secretary Kennedy Podcast so far seems designed to promote Trump administration talking points over any specific public health message

The Guardian - US

Earnings Preview: What to Expect From Pfizer’s Report

Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.

Barchart

Elon Musk reveals he ‘felt like he was dying’ after a COVID vaccine shot; says the virus was just a bad cold

Tech mogul Elon Musk sparked global vaccine debate by sharing his severe reaction to a COVID-19 vaccine dose, contrasting it with a mild virus infection. His remarks followed testimony by a former Pfizer toxicologist raising concerns about vaccine safety. Health authorities, however, continue to affirm the vaccines' safety and efficacy…

The Times of India

Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change

Pfizer CEO Albert Bourla warns U.S. and European universities are falling behind as Chinese institutions surge ahead in research output: “We need to become better.”

Fortune

He knows the pain of Lyme disease better than anyone, but RFK Jr. is about to make a decision that has health experts terrified

Here’s some big news in the fight against Lyme disease: Pfizer just announced its plan to file for regulatory approval of a new Lyme disease vaccine. If it gets the green light, this would be the first vaccine for the tick-borne illness available in over two decades. This new development,…

The Mary Sue

Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.

International Business Times

5 High-Yield Stocks to Shield Your Portfolio From the Storm

With the S&P 500 breaking below its 200-day SMA, high-yield dividend stocks are increasingly worth considering as a source of income and portfolio protection.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.

Barchart

Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their options.

Barchart

Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

Fortune

The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients

More than 5,000 shelved drug candidates were discontinued for business reasons, not safety ones. A new push aims to match them with the highest need.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start. Pfizer (PFE) has been a strong performer in 2026 and is up 9.64% so far this year.

Euronews

Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

The Guardian - US

RFK Jr’s pick to review Covid vaccines authored misleading research, experts say

HHS calls MIT professor ‘more than qualified’ for advisory panel and calls ‘attacks’ on him ‘politically motivated’

MarketBeat

The Dividend Safe Harbor: 2 Stocks to Watch

Rising geopolitical tensions, surging oil prices, and increasing volatility are pressuring U.S. equities and driving a shift toward defensive positioning.

Barchart

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

Kiplinger

Health Care Stocks Have Sagged. Can You Bet on a Recovery?

The flagging health care sector has perked up a bit lately. Is it time to invest?

Medical Daily

COVID-19 Vaccine Updates 2026: Booster Shots, Effectiveness, and Expert Guidance

COVID vaccines and booster shots 2025–2026 offer 80–95% protection against JN.1 and KP.2 variants, reducing severe illness and hospitalization.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.